BIOAFFINITY TECHNOLOGIES
BioAffinity Technologies applies experience, intelligence and creativity to the global fight against cancer. We know that by unlocking our personal potential, we make discoveries that give others an opportunity to live longer and more enjoyable lives. Our commitment is to continual scientific exploration, transparency and collaboration, and the development and commercialization of safer, more effective cancer treatments and patient-friendly tests that accurately diagnose early-stage cancer.
BIOAFFINITY TECHNOLOGIES
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-01-01
Address:
San Antonio, Texas, United States
Country:
United States
Website Url:
http://www.bioaffinitytech.com
Total Employee:
11+
Status:
Active
Contact:
(210)698-5334
Email Addresses:
[email protected]
Total Funding:
9.15 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Current Employees Featured
Investors List
Run Business Solutions
Run Business Solutions investment in Seed Round - BioAffinity Technologies
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-14 | bioAffinity Technologies Announces Xavier T. Reveles Promoted to Vice President of Operations |
Official Site Inspections
http://www.bioaffinitytech.com Semrush global rank: 5.86 M Semrush visits lastest month: 1.42 K
- Host name: 183.51.230.35.bc.googleusercontent.com
- IP address: 35.230.51.183
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "BioAffinity Technologies"
About Us - bioAffinity
As Chief Operating Officer at Inivata, Dr. Platt led the organization’s transition from research-stage through early commercialization, developing and launching two best-in-class liquid biopsy products, as well as establishing a $25 million … See details»
bioAffinity Technologies, Inc. (BIAF)
Apr 9, 2025 bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading … See details»
BioAffinity Technologies - Crunchbase Company Profile …
BioAffinity Technologies is a cancer diagnostics company that develops non-invasive, early-stage diagnostics to detect cancer and diseases. See details»
bioAffinity Technologies
Apr 3, 2025 BioAffinity Technologies was founded in 2000. Our founding team integrated biotechnology and pharmaceutical development technologies combined with novel microfluidic … See details»
BioAffinity Technologies: Revenue, Worth, Valuation
BioAffinity Technologies has an estimated revenue of $4.5M, and 24 employees. Alternatives of BioAffinity Technologies are Dermavant Sciences, Metrum... See details»
Home - bioAffinity Technologies
BioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer … See details»
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, …
May 20, 2025 For more information, visit www.bioaffinitytech.com. Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the … See details»
Company Profile for bioAffinity Technologies, Inc.
Jun 10, 2020 bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and … See details»
Company Profile for bioAffinity Technologies, Inc. - Business Wire
Jun 10, 2020 bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company addressing the significant unmet need for non-invasive, early-sta See details»
Company Information :: bioAffinity Technologies, Inc. (BIAF)
Contact Information Investor Relations Julie Anne Overton Director of Communications 3300 Nacogdoches Road Suite 216 San Antonio, TX 78217 T: 210-698-5334 … See details»
Company Profile for bioAffinity Technologies, Inc. - BioSpace
Jun 10, 2020 -- (BUSINESS WIRE)-- bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company addressing the significant unmet need for non-invasive, early-stage … See details»
bioAffinity Technologies Announces Targeted Actions to Cut $4 …
Mar 6, 2025 bioAffinity Technologies today announced strategic actions to cut $4 million in annual costs at its subsidiary CAP/CLIA pathology laboratory. See details»
bioAffinity Technologies Set for Continued Expansion in 2025
Dec 12, 2024 For more information, visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X. Forward-Looking Statements Certain statements in this press release … See details»
Corporate Governance :: bioAffinity Technologies, Inc. (BIAF)
As Chief Operating Officer at Inivata, Dr.Platt led the organization’s transition from research-stage through early commercialization, developing and launching two best-in-class liquid biopsy … See details»
bioAffinity Technologies Appoints New Chief Science Officer to ...
Nov 4, 2024 Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the … See details»
bioAffinity Technologies President and CEO Maria Zannes …
Jun 11, 2025 I look forward to working with the board to advance the association’s work in Texas.” About the American Lung Association The American Lung Association is the leading … See details»
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
May 6, 2025 bioAffinity Technologies announces the pricing of a best efforts offering of securities for aggregate gross proceeds of $3.25 million. See details»
bioAffinity Technologies Reports Record $9.4 Million Revenue for …
Mar 31, 2025 For more information, visit www.bioaffinitytech.com. Forward-Looking Statements Certain statements in this press release constitute “forward-looking statements” within the … See details»
bioAffinity Technologies Announces Closing of $3.25 Million …
May 7, 2025 bioAffinity Technologies today closed the previously announced best efforts offering of securities for aggregate gross proceeds of $3.25 million. See details»
bioAffinity Technologies Scientists Present Breakthrough Cancer ...
5 days ago For more information, visit www.bioaffinitytech.com. Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the … See details»